Search Results - "Tuthill, Mark H."

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study by Lee, Lennard Y W, Starkey, Thomas, Ionescu, Maria C, Little, Martin, Tilby, Michael, Tripathy, Arvind R, Mckenzie, Hayley S, Al-Hajji, Youssra, Barnard, Matthew, Benny, Liza, Burnett, Alexander, Cattell, Emma L, Charman, Jackie, Clark, James J, Khan, Sam, Ghafoor, Qamar, Illsley, George, Harper-Wynne, Catherine, Hattersley, Rosie J, Lee, Alvin J X, Leonard, Pauline C, Liu, Justin K H, Kinloch, Emma, Lam, Emily, Murphy, Gillian, Rhodes, Malcolm, Robinson, Kate, Pang, Matthew, Pascoe, Jennifer S, Platt, James R, Potter, Vanessa A, Randle, Amelia, Rigg, Anne S, Robinson, Tim M, Roques, Tom W, Roux, René L, Rozmanowski, Stefan, Tuthill, Mark H, Watts, Isabella, Williams, Sarah, Iveson, Tim, Lee, Siow Ming, Middleton, Gary, Middleton, Mark, Protheroe, Andrew, Fittall, Matthew W, Fowler, Tom, Johnson, Peter

“…People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first…”
Get full text

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study by Lee, Lennard Y.W., Ionescu, Maria C., Starkey, Thomas, Little, Martin, Tilby, Michael, Tripathy, Arvind R., Mckenzie, Hayley S., Al-Hajji, Youssra, Appanna, Nathan, Barnard, Matthew, Benny, Liza, Burnett, Alexander, Cattell, Emma L., Clark, James J., Khan, Sam, Ghafoor, Qamar, Panneerselvam, Hari, Illsley, George, Harper-Wynne, Catherine, Hattersley, Rosie J., Lee, Alvin JX, Lomas, Oliver, Liu, Justin KH, McCauley, Amanda, Pang, Matthew, Pascoe, Jennifer S., Platt, James R., Patel, Grisma, Patel, Vijay, Potter, Vanessa A., Randle, Amelia, Rigg, Anne S., Robinson, Tim M., Roques, Tom W., Roux, René L., Rozmanowski, Stefan, Taylor, Harriet, Tuthill, Mark H., Watts, Isabella, Williams, Sarah, Beggs, Andrew, Iveson, Tim, Lee, Siow M., Middleton, Gary, Middleton, Mark, Protheroe, Andrew, Fittall, Matthew W., Fowler, Tom, Johnson, Peter, Kinloch, Emma, Lam, Emily, Murphy, Gillian, Rhodes, Malcolm, Robinson, Kate, Swarup, Sanskriti, Bernhardt, Keeley, Bytyci, Jola, Ying, Yuxin, Johal, Sukhmunni, Sheehan, Remarez

“…People living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory…”
Get full text

Changing Practice Evaluation—Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols—Experience From a Supraregional Center by Tyrrell, Helen E.J., Church, David N., Joseph, Johnson, Traill, Zoe C., Sullivan, Mark E., Tuthill, Mark H., Verrill, Clare L., Pintus, Elias P., Dallas, Nicola L., Rogers, Paul B., Redgwell, Jacqueline, Protheroe, Andrew S.

“…Stage 1 seminomas treated by orchiectomy (501 cases) were analyzed to identify the risk factors for recurrence and methods of relapse detection. Rete testis…”
Get full text

Calcific uremic arteriolopathy presenting with small and large bowel involvement by Tuthill, Mark H, Stratton, Jonathan, Warrens, Anthony N

“…Calcific uremic arteriolopathy (CUA) is a rare complication of end-stage renal disease in which thrombosis occurs in calcified arteries, leading to infarction…”
Get more information

Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study by Atkins, Michael B., Ghatalia, Pooja, Merchan, Jaime R., George, Saby, Haanen, John, Gurney, Howard, Ravilla, Rahul, Van Der Veldt, Astrid Aplonia Maria, Beuselinck, Benoit, Pokataev, Ilya, Suelmann, Britt, Tuthill, Mark H., Vaena, Daniel A., Zagouri, Flora, Lin, Jianxin, Perini, Rodolfo F., Liu, Yanfang, Brugarolas, James, Agarwal, Neeraj

“…4534 Background: In the randomized phase 2 LITESPARK-013 study (NCT04489771), the first-in-class HIF-2α inhibitor belzutifan showed comparable antitumor…”
Get full text

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells by Tuthill, M H, Montinaro, A, Zinngrebe, J, Prieske, K, Draber, P, Prieske, S, Newsom-Davis, T, von Karstedt, S, Graves, J, Walczak, H

“…Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells while sparing normal tissues. Despite promising preclinical…”
Get full text